Historical Valuation
Lantern Pharma Inc (LTRN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.15. The fair price of Lantern Pharma Inc (LTRN) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.49
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lantern Pharma Inc (LTRN) has a current Price-to-Book (P/B) ratio of 3.58. Compared to its 3-year average P/B ratio of 1.81 , the current P/B ratio is approximately 98.37% higher. Relative to its 5-year average P/B ratio of 1.79, the current P/B ratio is about 99.92% higher. Lantern Pharma Inc (LTRN) has a Forward Free Cash Flow (FCF) yield of approximately -48.48%. Compared to its 3-year average FCF yield of -34.50%, the current FCF yield is approximately 40.53% lower. Relative to its 5-year average FCF yield of -25.80% , the current FCF yield is about 87.92% lower.
P/B
Median3y
1.81
Median5y
1.79
FCF Yield
Median3y
-34.50
Median5y
-25.80
Competitors Valuation Multiple
AI Analysis for LTRN
The average P/S ratio for LTRN competitors is 5.93, providing a benchmark for relative valuation. Lantern Pharma Inc Corp (LTRN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for LTRN
1Y
3Y
5Y
Market capitalization of LTRN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LTRN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LTRN currently overvalued or undervalued?
Lantern Pharma Inc (LTRN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.15. The fair price of Lantern Pharma Inc (LTRN) is between to according to relative valuation methord.
What is Lantern Pharma Inc (LTRN) fair value?
LTRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lantern Pharma Inc (LTRN) is between to according to relative valuation methord.
How does LTRN's valuation metrics compare to the industry average?
The average P/S ratio for LTRN's competitors is 5.93, providing a benchmark for relative valuation. Lantern Pharma Inc Corp (LTRN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Lantern Pharma Inc (LTRN) as of Jan 09 2026?
As of Jan 09 2026, Lantern Pharma Inc (LTRN) has a P/B ratio of 3.58. This indicates that the market values LTRN at 3.58 times its book value.
What is the current FCF Yield for Lantern Pharma Inc (LTRN) as of Jan 09 2026?
As of Jan 09 2026, Lantern Pharma Inc (LTRN) has a FCF Yield of -48.48%. This means that for every dollar of Lantern Pharma Inc’s market capitalization, the company generates -48.48 cents in free cash flow.
What is the current Forward P/E ratio for Lantern Pharma Inc (LTRN) as of Jan 09 2026?
As of Jan 09 2026, Lantern Pharma Inc (LTRN) has a Forward P/E ratio of -1.99. This means the market is willing to pay $-1.99 for every dollar of Lantern Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lantern Pharma Inc (LTRN) as of Jan 09 2026?
As of Jan 09 2026, Lantern Pharma Inc (LTRN) has a Forward P/S ratio of 0.00. This means the market is valuing LTRN at $0.00 for every dollar of expected revenue over the next 12 months.